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Complex neural circuits within the hypothalamus that govern essential autonomic
processes and associated behaviors signal using amino acid and monoamine transmitters
and a variety of neuropeptide (hormone) modulators, often via G-protein coupled receptors
(GPCRs) and associated cellular pathways. Relaxin-3 is a recently identified neuropeptide
that is highly conserved throughout evolution. Neurons expressing relaxin-3 are located
in the brainstem, but broadly innervate the entire limbic system including the hypothala-
mus. Extensive anatomical data in rodents and non-human primate, and recent regulatory
and functional data, suggest relaxin-3 signaling via its cognate GPCR, RXFP3, has a broad
range of effects on neuroendocrine function associated with stress responses, feeding
and metabolism, motivation and reward, and possibly sexual behavior and reproduction.
Therefore, this article aims to highlight the growing appreciation of the relaxin-3/RXFP3
system as an important “extrinsic” regulator of the neuroendocrine axis by reviewing its
neuroanatomy and its putative roles in arousal-, stress-, and feeding-related behaviors and
links to associated neural substrates and signaling networks. Current evidence identifies
RXFP3 as a potential therapeutic target for treatment of neuroendocrine disorders and
related behavioral dysfunction.
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INTRODUCTION
Precise regulation of complex neural circuits in the hypo-
thalamus governs essential autonomic processes and associ-
ated behaviors, such as metabolism, growth, and feeding; stress
responses, arousal, and locomotor activity; as well as reproduc-
tion and social/sexual behavior (1–7). These intrinsic and often
interacting neural circuits utilize various neuroendocrine pep-
tides/hormones, such as thyrotropin-releasing hormone (TRH),
growth hormone-releasing hormone (GHRH), somatostatin,
orexins, melanin-concentrating hormone (MCH), agouti-related
peptide (AgRP), pro-opiomelanocortin (POMC) gene products
[alpha-melanocyte-stimulating hormone (α-MSH)], neuropep-
tide Y (NPY), corticotropin-releasing hormone (CRH) and uro-
cortins, gonadotropin-releasing hormone (GnRH), arginine vaso-
pressin (AVP), and oxytocin (8–16). The majority of these
peptides and hormones signal via G-protein coupled receptors
(GPCRs) and often multiple receptors exist for different mem-
bers of a peptide family or for the same peptide modulator
[e.g., Ref. (17–19)].
This combination of a large number of ligands and multiple
receptors results in a vast diversity in the potential regulation
of different populations of hypothalamic neurons. For exam-
ple, a recent survey revealed more than 300 different GPCRs
are expressed by the heterogeneous neurons in the paraven-
tricular (PVN) and supraoptic nuclei (SON) alone (20). This
diversity of potential functional regulation provides a challenge
for neuroscientists and neuroendocrinologists to document the
anatomical distribution and dissect the primary and integrative
actions of different signaling systems, both within hypothalamic
circuits and via their descending and ascending inputs. Impor-
tantly, modern experimental approaches including conventional
and viral-based tract-tracing (21) and other viral-based methods,
such as optogenetics and DREADD technology (22–25), com-
bined with molecular genetics and complementary methods for
measuring changes in physiology and behavior, are successfully
dissecting the role of individual neuron populations and the
key mediators involved. In turn, this is allowing a reappraisal
of the “dogma” related to the function of several established
neural transmitter and hormone networks in the hypothalamus
and the integration of new “chemical players” into the existing
circuitry.
Just over a decade ago, the final member of the relaxin and
insulin-like peptide superfamily was discovered and named H3
relaxin (human) or relaxin-3 (rodents), in line with the prior dis-
covery and characterization of two other relaxin genes in humans
(26). However, unlike its related peptide, H2 relaxin or relaxin,
which is widely distributed within the brain and peripheral tis-
sues [see Ref. (27, 28) for review], relaxin-3 was found to be most
highly expressed in brain (26, 29). In 2003, GPCR135 (now known
as RXFP3) was identified as the cognate relaxin-3 receptor (30, 31)
and was shown to be highly localized in various rat brain areas
(30, 32), which were later confirmed to contain relaxin-3-positive
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axonal projections and terminations (33). A similar central distri-
bution of relaxin-3 neurons and projections to that reported in
the rat was subsequently observed in the mouse [Ref. (34); Allen
Brain Atlas1] and macaque brain (35, 36), suggesting that this
neuropeptide system has been highly conserved throughout evo-
lution. Indeed, bioinformatic studies revealed that a relaxin-3-like
ancestral peptide gave rise to the relaxin and insulin-like peptide
superfamily and its sequence has been highly conserved by strong
purifying selection, consistent with a highly conserved function in
the central nervous system (37, 38).
After their discovery, characterization of the neuroanatomical
distribution of relaxin-3- and RXFP3-expressing neurons pro-
vided insights into putative functions of relaxin-3; and a growing
number of experimental studies have subsequently confirmed
roles for relaxin-3/RXFP3 signaling in arousal, feeding, stress
responses, and cognition [see Ref. (39) for review]. Several of these
actions of relaxin-3 likely involve effects on RXFP3-positive hypo-
thalamic neuron populations. Therefore, in this article we will
provide a summary of the hypothalamic distribution of RXFP3
1www.brain-map.org
mRNA and protein, and relaxin-3 projections, a concise review of
experimental data indicating that this neuropeptide/receptor sys-
tem is a modulator of hypothalamic function, and a perspective
on the future studies required to better understand this system and
to exploit its therapeutic potential.
NEUROANATOMY OF THE RELAXIN-3/RXFP3 SYSTEM
Relaxin-3 is a 5 kDa peptide that shares common structural fea-
tures with all relaxin and insulin-like peptide family members – an
A- and B-chain held together by three disulfide bonds (26, 40,
41). The native peptide is synthesized as a pre-prohormone that
is subsequently cleaved by proteolytic processing of the signal
and C-peptides to form the mature peptide [see e.g., Ref. (42,
43)]. Early in situ hybridization studies revealed that relaxin-3
mRNA was highly expressed by a cluster of neurons in the rat
pontine central gray, identified as the ventromedial dorsal tegmen-
tal area (29), more commonly known as the nucleus incertus
[NI; (44, 45)]. Smaller dispersed populations were also iden-
tified in the medial periaqueductal gray (PAG), pontine raphe
(PR), and a region dorsal of the substantia nigra (dSN) in
the rat (33, 46), mouse (34), and macaque (36) (Figure 1).
FIGURE 1 | Distribution of the relaxin-3 neural network and RXFP3 in
relation to RXFP1, illustrated on a schematic parasagittal profile of the
rodent brain. Relaxin-3 immunoreactive fibers (red), RXFP3 binding sites
(yellow), RXFP1 binding sites (blue), and regions that contain both RXFP1
and RXFP3 binding sites (green) are illustrated [see (32–34, 46, 62) and
(28)]. Amy, amygdala; Arc, arcuate nucleus; BNST, bed nucleus of the stria
terminalis; CM, centromedial thalamic nucleus; CPu, caudate putamen; Cx,
cerebral cortex; DBB, diagonal band of Broca; DG, dentate gyrus; DMH,
dorsomedial nucleus of hypothalamus; DR, dorsal raphe nucleus; DTg,
dorsal tegmental nucleus; Hb, habenula; Hi, hippocampus; IC, inferior
colliculus; IGL, intergeniculate leaflet; IPN, interpeduncular nucleus; LH,
lateral hypothalamus; MPA, medial preoptic area; MS, medial septum; NI,
nucleus incertus; OB, olfactory bulb; Orb, orbitofrontal cortex; PAG,
periaqueductal gray; PH, posterior hypothalamus; PnR, pontine raphe; PVA,
paraventricular thalamic area; PVN, paraventricular nucleus of hypothalamus;
SC, superior colliculus; SFO, subfornical organ; SON, supraoptic nucleus;
SN, substantia nigra; SuM, supramammillary nucleus; Th, thalamus; VP,
ventral pallidum. Adapted from a figure kindly provided by Dr. Craig Smith
(The Florey Institute of Neuroscience and Mental Health, Melbourne,
Australia).
Frontiers in Endocrinology | Neuroendocrine Science September 2013 | Volume 4 | Article 128 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ganella et al. Relaxin-3/RXFP3 signaling and neuroendocrine responses
Ultrastructural analysis of relaxin-3 immunoreactivity in the rat
NI identified the peptide in the rough endoplasmic reticulum
and Golgi apparatus in the cell soma and within dense-core vesi-
cles adjacent to synapses in nerve terminals of distant target
regions such as the lateral hypothalamus (46) and medial sep-
tum (47), indicating that relaxin-3 is processed and released as a
transmitter.
The efferent and afferent connections of the rat NI have
been characterized (44, 45, 48–50) and many NI projection
target regions, including the hypothalamus, contain relaxin-3
immunoreactive fibers and terminals, and neurons expressing
RXFP3 (33, 50) (Figure 1; Table 1), suggesting many of these
areas are innervated by NI relaxin-3 neurons. Not surprisingly, NI
relaxin-3 neurons have been the focus of the majority of func-
tional studies to date, which indicate they are highly responsive to
neurogenic stressors and CRH (46, 51–53).
Less is known about the connections, regulation and func-
tion of other relaxin-3 neuron populations, but a recent study
demonstrated that PAG relaxin-3 neurons strongly innervate and
modulate neuronal activity in the intergeniculate leaflet [IGL;
(46, 54, 55)], a region that is known to contribute to the reg-
ulation of arousal and circadian activity (56–58). In brain slice
studies, patch-clamp recordings of IGL neurons, revealed that acti-
vation of RXFP3 by bath application of the agonist peptide, R3/I5,
produced depolarization of identified NPY-containing neurons
(55), which are known to project to the suprachiasmatic nucleus
via the geniculohypothalamic tract (56, 58). Neurons in the IGL
also project to a number of other hypothalamic areas, including
the anterior and lateral hypothalamic areas, and the dorsomedial
nucleus (58).
There are, however, several brain regions like the afore-
mentioned IGL and the amygdala that contain dense relaxin-3
immunoreactivity and/or RXFP3, but sparse NI projections; sug-
gesting they are also more strongly innervated by other relaxin-3
populations. In fact, there is anatomical evidence, chiefly from
neural tract-tracing studies, to suggest the various RXFP3-positive
regions in the hypothalamus are also innervated by relaxin-3 neu-
rons in the NI and other relaxin-3 groups. For example, a recent
study of brainstem inputs to the PVN and surrounding area in the
rat (59) revealed projections from the medial PAG, PR, and “dorsal
to substantia nigra” regions, which contain relaxin-3 neurons.
RXFP3 has been localized in various subregions of the hypo-
thalamus in the rat (32, 33) mouse (34, 60) (Table 1), and macaque
(36). The highest densities are present in the PVN, SON and adja-
cent medial (MPO) and lateral preoptic (LPO) nuclei, but there are
RXFP3-positive neurons in other hypothalamic areas, including
the periventricular nucleus (33, 34) (Table 1), which is consistent
with a putative role of relaxin-3/RXFP3 signaling in the control of
a range of homeostatic and autonomic behaviors via modulation
of related hypothalamic networks.
RELAXIN-3 RECEPTOR BINDING AND ACTIVATION IN BRAIN
Effects of endogenous relaxin-3 are predicted to be mediated by
its cognate receptor, RXFP3, but relaxin-3 is also an agonist at the
relaxin-family receptors, RXFP1 and RXFP4, when administered at
pharmacological doses, albeit with lower potency than at RXFP3
Table 1 | Comparative distribution of relaxin-3 and its receptor, RXFP3, in hypothalamic regions of rat and mouse brain.
Hypothalamic area/nucleus RLN3-LI RXFP3 mRNA RXFP3 binding sites
Mouse Rat Mouse Rat Mouse Rat
Anterior hypothalamic n. −/+ ++ + ++ −/+ +
Arcuate n. − + + + − −/+
Dorsomedial hypothalamic n. + +++ + +++ + n.r.
Lateral hypothalamic area +++ +++ ++ ++ + +
Lateral mammillary n. ++ + −/+ −/+ − −
Lateroanterior hypothalamic n. −/+ ++ + ++ − n.r.
Medial mammillary n. + ++ − + − −
Paraventricular hypothalamic n. + ++ +++ +++ +++ +++
Periventricular hypothalamic n. −/+ + +++ ++ ++ ++
Posterior hypothalamic area +++ +++ ++ + + n.r.
Premammillary n. + ++ + + + n.r.
Preoptic area, lateral ++ +++ ++ ++ ++ +
Preoptic area, medial −/+ ++ + +++ −/+ −/+
Suprachiasmatic n. + −/+ + −/+ − −
Supramammillary n. +++ +++ ++ ++ −/+ −
Supraoptic n. +++ ++ +++ +++ ++ +++
Tuberomammillary n. + +++ + +++ + n.r.
Ventromedial hypothalamic n. +/++ ++ + ++ + n.r.
Relative abundance values are given: − not detectable, + low density, ++ moderate density, +++ high density, n.r. not reported). Adapted from Ma et al. (33),
Smith et al. (34), Sutton et al. (32), Tanaka et al. (46), Allen Brain Institute Brain Atlas (http:// mouse.brain-map.org/ experiment/ show/ 71358555). RLN3-LI, relaxin-3
like immunoreactivity.
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(30, 61). RXFP1 and RXFP4 are likely expressed in the human
brain, along with RXFP3, but based on animal studies these recep-
tors and the peptides which bind and activate them (relaxin,
insulin-like peptide 5, and relaxin-3, respectively) are expressed
in quite distinct regions of the brain and at very different levels
[e.g., Ref. (26, 29, 30, 33, 46, 62)], so a current working hypothesis
that can be tested is that these receptors mediate distinct func-
tional effects in the brain, which modulate different homeostatic
processes and behaviors.
Cell signaling events associated with the relaxin-family recep-
tors have been studied in different cell lines transfected with the
human receptors (28, 63) and activation of RXFP1 and RXFP3/4
by H3 relaxin leads to different intracellular responses in vitro. In
Chinese hamster ovary (CHO) cells, RXFP3 and RXFP4 couple
to the inhibitory Gαi/Gαo-protein system and receptor activa-
tion leads to sequestration of these G-proteins and inhibition of
adenylate cyclase (AC), and subsequent cAMP accumulation (30,
64). The intracellular signaling pathway of the relaxin-3-RXFP3
interaction has also been studied in the SN56 neuronal-like cell
line, in which the Gαi/Gαo pathway was recruited, suggesting an
inhibitory intracellular pathway may be activated in vivo when
relaxin-3 binds to RXFP3-expressing neurons within the brain
(63), an idea that can be tested in different functional networks [see
Ref. (54, 55)]. In contrast, RXFP1 activation by either relaxin or
relaxin-3 in mammalian cell expression systems initiates a down-
stream accumulation of cAMP, as it is predominantly coupled to
the stimulatory Gs-protein. These in vitro studies suggest acti-
vation of different receptors may lead to different downstream
effects in neurons in vivo. Little is known, however, about the
native intracellular signaling of any of the relaxin family of recep-
tors (RXFP1–RXFP4) in specific neuronal populations, apart from
a recent in vitro study that revealed activation of RXFP3 by the
agonist peptide, R3/I5 (65), produced depolarization of identi-
fied NPY-containing neurons and hyperpolarization of adjacent
non-NPY neurons (55).
Although there is no definitive evidence that major biological
effects mediated by relaxin-3 are caused by activation of either
RXFP1 and/or RXFP4, the ability of relaxin-3 to activate RXFP1
and RXFP4 as well as RXFP3 must be considered as a confounding
factor when using pharmacological doses of peptides in vivo, in
attempts to study neuropeptide function in the rodent. From a
practical viewpoint, the rat is suited to studies of the neurobiology
of relaxin-3/RXFP3 signaling, since RXFP4 is a pseudogene in this
species, and so not a “confound.” However, in situ hybridization
and radioligand binding site studies indicate RXFP1 is expressed
in the rat brain in a number of regions positive for RXFP3, includ-
ing the cerebral cortex, amygdala, thalamus, and hypothalamus
(32, 33, 62). Consequently RXFP1 activity must be considered
in studies of exogenous relaxin-3 peptide administration [e.g.,
Ref. (40, 66–70)]. The relative degree to which RXFP1 activation
has impacted outcomes in studies of relaxin-3 actions within the
hypothalamus and other brain areas is hard to gage, although in
some cases comparative effects of relaxin were reported [see Ref.
(71) below]. Fortunately, the development more recently of ago-
nist and antagonist peptides which selectively activate or inhibit
RXFP3 [e.g., Ref. (65, 72–74)] has facilitated investigations of the
behavioral and physiological effects of specific relaxin-3/RXFP3
interactions. Indeed, several studies have used these peptides to
assess relaxin-3/RXFP3 related functions associated with the hypo-
thalamus, although their use is not as widespread as it might
be [e.g., Ref. (69, 70)], particularly in light of the availability
of a chemically less-complex, single-chain peptide antagonist for
RXFP3 (73).
ACTIONS OF THE RELAXIN-3/RXFP3 SYSTEM – FOCUS ON
HYPOTHALAMUS
FEEDING AND ENERGY BALANCE
The PVN and arcuate nucleus (ARC) are two hypothalamic nuclei
which tightly regulate food intake and energy homeostasis [e.g.,
Ref. (3, 4, 12, 15, 75)]. Relaxin-3 immunoreactivity and RXFP3
mRNA and binding sites have been identified in the PVN and ARC
(30, 32, 33) (Table 1) and extensive research has demonstrated that
H3 relaxin can alter feeding and appetite in rats [see Ref. (76)].
Central (icv) administration of H3 relaxin caused hyperphagia in
satiated male Wistar rats in the first hour after treatment in both
the light and the dark phase, while equivalent doses of H2 relaxin
did not produce a similar effect (66). The doses of H3 relaxin
administered icv (180 pmol) or directly into the PVN (18 pmol) at
which a significant increase in feeding was observed (see below)
were similar to doses of other “feeding” peptides which elicit an
increased feeding response upon similar administration [e.g., NPY
∼80 pmol iPVN; (77)], consistent with a physiological role for
relaxin-3/RXFP3 signaling in modulating appetite and feeding
behavior. Importantly, icv administration of the selective agonist,
R3/I5, produced an increase in first-hour food intake and this
effect was inhibited by co-administration of the selective antago-
nist,∆R3/I5 (72), further suggesting RXFP3 involvement. In these
feeding studies, the food intake was monitored for only 24 h post-
injection, as it was predicted the injected peptide would be quite
rapidly degraded by proteolysis. In a study of longer term effects of
relaxin-3 on feeding and body weight, H3 relaxin (600 pmol/day)
was infused icv into rats for 14 days via osmotic mini-pump, which
produced a significant increase in food intake and body weight
gain, and plasma leptin and insulin levels, compared to vehicle
(78). This data indicated that the relaxin-3 induced increase in
food intake could be sustained and lead to an increase in body
weight and associated biochemical changes in the rat.
Given the primary role of the hypothalamus in energy balance,
the effect on feeding of local hypothalamic injections of relaxin-
3 was assessed. Acute H3 relaxin injection into the PVN (iPVN)
increased food intake over the first hour (67). Sub-chronic iPVN
H3 relaxin administration in ad libitum fed rats also produced an
increase in food intake and cumulative body weight gain c.f. vehi-
cle (67). These authors also used “Fos-activation” mapping after
icv administration of H3 relaxin to identify activated hypothala-
mic nuclei. In addition to the PVN, the SON, ARC, and anterior
preoptic area displayed increased Fos staining (79). When injected
directly into these and other hypothalamic nuclei H3 relaxin stim-
ulated a significant increase in food intake within the first hour,
relative to control (79), suggesting multiple hypothalamic nuclei
may mediate these potent orexigenic effects. Unfortunately the
potential involvement of RXFP1 activation in the observed effects
cannot be reliably excluded, as RXFP3-selective peptides were not
utilized. It is also possible the injected peptide is able to diffuse
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from the injection site to adjacent areas that are primarily involved
in the activation of feeding, although some targeted sites were not
associated with feeding (79).
In order to circumvent issues associated with acute peptide
administration and cross-reactivity of H3 relaxin at RXFP1, we
used a viral strategy to investigate the effect of chronic R3/I5
mediated RXFP3 activation within the hypothalamic PVN (43).
Using a recombinant adeno-associated virus (rAAV) engineered
to locally secrete bioactive R3/I5 (rAAV-R3/I5), we demonstrated
an increase in food intake in the R3/I5 expressing rats (∼5.2 g/day
more than control) which was sustained for up to 2 months, lead-
ing to an ∼23% increase in cumulative body weight gain (43). In
an attempt to identify targets of RXFP3 activation within the hypo-
thalamus, levels of mRNA for a number of genes were also assessed
in dissected hypothalamic tissue blocks using quantitative reverse
transcription PCR. Notably, no major differences were identified
in expression of some “major” feeding peptide genes (NPY, AgRP,
POMC) between rAAV-R3/I5 and rAAV-control treated groups,
whereas the levels of oxytocin and AVP mRNA were altered. This is,
however, consistent with the strong expression of RXFP3 by neu-
rons in the PVN and SON (30, 32, 33) (Table 1), which contain
oxytocin- and AVP-containing magnocellular neurons. Chronic
viral-mediated expression of R3/I5 in the hypothalamus for up to
∼14 weeks led to a marked reduction in oxytocin mRNA expres-
sion in PVN (∼50%) and a smaller reduction in AVP (∼25%),
compared to control expression (43). These data suggest the acute
orexigenic effect of RXFP3 activation may be mediated by changes
in oxytocin release (and perhaps AVP) [see Ref. (80)], an idea that
can be tested experimentally. Furthermore, there is a substantial
literature relating to oxytocin as a satiety factor that also supports
this putative acute and chronic mechanism of action.
INTERACTION WITH OXYTOCIN AND ARGININE VASOPRESSIN
SYSTEMS IN THE PVN
Oxytocin is a peptide hormone highly expressed in magnocel-
lular and some parvocellular neurons of the hypothalamic PVN
and SON (81–83). Oxytocin is classically known as a reproductive
hormone with roles in parturition, lactation, sexual behavior, and
pair bonding and attachment [see Ref. (84, 85) for review]. How-
ever, early studies revealed that central administration of oxytocin
dose-dependently reduced food consumption and time spent eat-
ing and increased the latency to the first meal in pre-fasted rats;
an effect prevented by co-administration of an oxytocin receptor
antagonist (86). A number of studies have since confirmed cen-
tral oxytocin administration inhibits food intake, strengthening
the hypothesis that oxytocin serves a key role in appetite control
(87–89). More recent data is consistent with this view, as oxy-
tocin null mutation mice display enhanced intake of sweet and
non-sweet carbohydrate solutions (90, 91) and develop late-onset
obesity (92).
The magnitude of the increase in feeding and body weight gain
observed in our hypothalamic R3/I5 expression studies (43) was
modest relative to those seen after similar viral-mediated NPY
and AgRP over-expression, consistent with actions independent of
direct effects on these neurons. The down-regulation of oxytocin
and AVP mRNA expression observed (43), suggests the R3/I5 ago-
nist peptide is activating RXFP3 on oxytocin- and AVP-containing
neurons, which results in downstream effects on the transcrip-
tion of oxytocin and AVP mRNA in these neurons (e.g., Ref.
(93, 94)] and subsequent effects on production and release of
this anorexigenic hormone. If RXFP3 associated cell signaling in
these neurons is similar to effects reported in vitro, this could be
associated with reduction in cellular cAMP levels (via inhibitory
Gi-protein coupling) and inhibition or hyperpolarization of target
neurons – a possibility that can be assessed experimentally using
in vitro or in vivo electrophysiological and biochemical methods
[e.g., Ref. (55, 95)].
It is also necessary to establish whether it is the proposed
reduction in oxytocin production and release which produces
the observed increase in food intake in AAV-R3/I5-treated rats,
or whether the chronic increase in food intake caused by hypo-
thalamic RXFP3 activation over time leads to down-regulation of
oxytocin mRNA via a distinct mechanism. This could be explored
by conducting acute peptide administration studies or shorter
time course viral infusion studies, and assessing oxytocin mRNA,
peptide and release levels, before any marked changes in body
weight have occurred.
Indeed, a recent study examined the effect of icv H3 relaxin on
anxiety-like behavior in rats and observed an anxiolytic effect in
the elevated plus maze test and the shock probe-burying test (70),
consistent with our studies demonstrating that icv administration
of a selective RXFP3 agonist peptide reduced anxiety-like behavior
in the light-dark box and elevated plus maze (96). Notably, these
authors used microarray and peptidomics approaches to iden-
tify associated downstream signaling targets in the hypothalamus
altered by icv H3 relaxin and detected a relatively acute (6–24 h)
and quite specific increase in the level of hypothalamic oxytocin
mRNA and peptide levels (70). This data is, however, more consis-
tent with the ability of H3 relaxin to activate neurons via RXFP1
[see e.g., Ref. (40, 67, 68)] rather than via RXFP3, which based on
predicted signaling (28, 63) might be expected to decrease oxy-
tocin neuron activity (and mRNA and peptide levels), as seen in
our study (43). Therefore, further studies are required to identify
specific effects of RXFP3 (and RXFP1) activation in hypothalamus
and other areas in altered feeding and metabolism and anxiety-like
behavior (76, 96).
Further evidence for an association of a down-regulation/
inhibition of PVN oxytocin activity with a hyperphagic phe-
notype was reported recently. Optogenetic electrophysiological
studies revealed that GABA/AgRP neurons in the ARC project
to a population of oxytocin neurons in the PVN and strongly
inhibit their activity, and this suppression of oxytocin neurons by
AgRP neuronal activation drives evoked feeding (23). This study
also demonstrated that increased food seeking and consumption
in response to GABA/AgRP neuron activation is similarly induced
by suppressing the activity of the PVN neurons that (selectively)
express the single-minded 1 (SIM1) transcription factor (23, 97).
Importantly from a clinical perspective, a number of dis-
ease states in which hyperphagia is a symptom are associated
with hypothalamic oxytocin dysregulation. A small population
of PVN oxytocin neurons is selectively lost in Prader–Willi syn-
drome, which is a condition involving insatiable hunger (98); and
disruption of synaptic release of hypothalamic oxytocin results in
overeating (99). Oxytocin deficits in SIM1 haploinsufficient mice
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and mutations in the SIM1 gene in humans lead to hyperphagic
obesity (97, 100, 101). In the mouse model, an∼80% reduction in
oxytocin and ∼30% reduction in AVP was observed (97). These
studies illustrate that modulation of relaxin-3 signaling and asso-
ciated alterations in oxytocin neuron activity may be a fruitful area
to explore for treating disease states associated with eating disor-
ders. For example, a recent clinical cross-sectional study reported
that female patients with anorexia nervosa, characterized by food
restriction, low weight, and hypoleptinemia, had higher mean cir-
culating oxytocin levels than healthy controls at all times assessed
(102). The severity of disease psychopathology was also positively
associated with circulating oxytocin levels (102).
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND STRESS RESPONSES
Integration of the stress response via the hypothalamic-pituitary-
adrenal (HPA) axis occurs via interaction between brain areas
which are sensitive to stress and neuroendocrine neurons of the
hypothalamic PVN, particularly those in the parvocellular region
producing CRH [see Ref. (1, 6, 103) for review]. CRH stimu-
lates the secretion and synthesis of adrenocorticotropin hormone
(ACTH) from the pituitary and is the main regulator of HPA axis
activity during stress.
Early regulatory studies revealed that neurons in the NI and
specifically relaxin-3 expressing neurons respond to stress and
CRH (46, 104), and that relaxin-3-containing neurons in the NI
express CRH type 1 receptors (CRH-R1) (46). Upon icv admin-
istration of CRH, 65% of relaxin-3-positive neurons underwent
activation (detected using Fos-immunostaining 2 h post-infusion)
(46). Electrophysiological characterization of NI neurons revealed
that a significant population increased firing following icv admin-
istration of CRH, of which the majority were relaxin-3-positive,
though an almost equal number of non-relaxin-3 neurons exhib-
ited a decrease in firing in the anesthetized rat (53). These find-
ings are consistent with semi-quantitative immunohistochemical
studies of the NI revealing this heterogeneous neuron popula-
tion consists of relaxin-3 neurons that all co-express CRH-R1,
though not all CRH-R1 contain relaxin-3, in addition to a sig-
nificant population that are CRH-R1 negative (53). Rats tested in
a water immersion-restraint stress paradigm, displayed increased
Fos-immunostaining and an up-regulation of relaxin-3 mRNA in
NI neurons (46). Subsequently, the effect of a repeat forced swim
on relaxin-3 expression in the NI was examined and led to a rapid
increase in relaxin-3 mRNA expression (51). This increase was
largely mediated by CRH activation of CRH-R1 located on NI
neurons, as pre-treatment with the CRH antagonist, antalarmin,
reduced the increase in relaxin-3 mRNA expression by 70–80%.
Levels of relaxin-3 heteronuclear (hn) RNA were also increased in
NI neurons after the repeat forced swim (51). Changes in hnRNA
are a measure of transcriptional activity and are thought to reflect
the level of encoded peptide synthesis (105), suggesting in this
case, an increase in relaxin-3 utilization.
Initial insights into the hypothalamic action of relaxin-3 in
relation to the stress response have been obtained by monitor-
ing the effect of icv administration of relaxin-3 in male rats (69).
Increased Fos staining in the PVN and SON was observed 1 h
post-administration and levels of c-fos and CRH mRNA in the
PVN were also increased 2 h after H3 relaxin administration.
Central H3 relaxin administration also elicited an increase in circu-
lating plasma ACTH (69). These data suggest a role for relaxin-3 in
the acute hypothalamus-pituitary CRH-ACTH system response,
but these studies did not directly identify the presence of RXFP3 on
CRH neurons or measure the direct acute excitatory or inhibitory
effect of RXFP3 activation on these neurons [see Ref. (55)].
Notably, a recent report also suggests sex-specific regulation
of CRH and relaxin-3 systems in response to combined stres-
sors. Chronically stressed and repeatedly food-restricted female
rats consumed more standard chow during recovery and had
an increased bodyweight relative to controls, whereas male rats
exposed to this regime had a reduction in bodyweight (106).
Stressed/food-restricted female rats had elevated plasma corticos-
terone and low PVN CRH mRNA levels. CRH neurons in the
medial preoptic area were identified as a source of increased CRH
production/release during stress in female brain, i.e., CRH mRNA
levels in this area were – higher in female than male rats, increased
by chronic stress, and increased in female, not male, rats after
repeated food restriction (106).
Further studies are now required to determine precisely how the
robust, consistently observed stress and CRH-induced activation
of NI and relaxin-3 neurons (46, 51, 53, 106) directly or indirectly
activates (or possibly inhibits) the PVN and the main components
of the HPA axis; and whether and how these processes are regulated
by steroid and other hormones under different conditions.
EFFECTS ON REPRODUCTIVE NEUROENDOCRINE SYSTEMS
Preliminary studies have indicated a putative role for relaxin-
3 in reproductive physiology. Following injection into the PVN
and surrounds, H3 relaxin increased levels of marker hormones
of the hypothalamic-pituitary-gonadal (HPG) axis (71, 107);
and anatomical studies have identified RXFP3 in many areas in
the hypothalamus relevant to reproductive neuroendocrinology,
including the preoptic area and the PVN and SON (33). H3 relaxin
administered icv or iPVN significantly increased plasma luteiniz-
ing hormone (LH) levels 30 min post-injection in male Wistar rats,
an effect blocked by peripheral pre-treatment with a GnRH antag-
onist, consistent with increased central GnRH release (71). In these
initial studies, H2 relaxin administration via the same routes pro-
duced a small,non-significant increase in LH,suggesting a stronger
relaxin-3/RXFP3-mediated effect (71). Activity of the endoge-
nous peptide at RXFP1 cannot be completely excluded from an
involvement in these effects, however, as RXFP1 is expressed in the
anterior hypothalamus and PVN of the rat (62). If so, high levels
of endogenous relaxin-3 may act via RXFP1 to stimulate the HPG
axis, an idea that could be tested experimentally. It would also be
of interest to observe the effects of icv or iPVN administration of
RXFP3-selective peptides (65, 72–74) on the HPG axis in female
rats to check for similar hormone changes to those observed in
male rats.
Notably, treatment of mouse hypothalamic neuron-like (GT1–
7) cells or hypothalamic explants with synthetic H3 relaxin, pro-
duced a dose-dependent increase in secretion of GnRH (71).
However, it is again unclear if this is an RXFP3-mediated effect,
as GT1–7 cells and hypothalamic explants also express RXFP1;
and H3 relaxin binds and activates these receptors. As these cells
express both RXFP1 and RXFP3, the relaxin-3 mediated secretion
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of GnRH should be assessed for sensitivity to blockade with an
RXFP3 antagonist (71–73).
In our recent study, we assessed the effect of chronic
(∼14 weeks) viral-mediated expression of R3/I5 in the hypo-
thalamus on GnRH mRNA levels (43). Although the difference
between groups was not statistically significant, there was a trend
for increased GnRH mRNA levels in AAV-R3/I5-treated com-
pared to control rats, with considerable variability in individual
values. Given the dispersed nature of GnRH expressing neurons
in the hypothalamus, the variability observed suggests that dif-
ferent numbers (populations) of GnRH expressing neurons may
have been dissected in these assays and/or there may be a genuine
increase in GnRH transcription as a result of the treatment. This
important question needs to be further investigated using suitable
quantitative methods, in conjunction with further assessments of
relaxin3/RXFP3 indices relative to GnRH and other reproductive
peptides and receptors during different stages of pregnancy, birth
and lactation.
OTHER HYPOTHALAMIC SITES OF RELAXIN-3/RXFP3 ACTION
The relaxin-3/RXFP3 system may have actions in other hypo-
thalamic nuclei, demonstrated by the presence of both relaxin-3
immunoreactive fibers and RXFP3 mRNA/protein in the lateral
and medial preoptic areas, anterior, posterior, dorsomedial, and
ventromedial regions, and the adjacent supramammillary nucleus
(SuM) (33) (Table 1). The functions of these regions will be briefly
reviewed, in view of the postulated role of relaxin-3 in arousal,
feeding, behavioral state, and cognition (39).
The SuM receives a moderate relaxin-3 innervation in the rat
(33) and the mouse (34), and this nucleus represents a major tar-
get of the peptide network in the macaque brain (35). In contrast
to other “hypothalamic” regions, this nucleus is best characterized
as a key input to and modulator of the hippocampus and hip-
pocampal theta rhythm (108, 109), a synchronous activity between
4 and 12 Hz associated with active waking behavior and REM
sleep (110), mnemonic processing (111, 112), spatial navigation
and exploration (113), and sensorimotor integration (114, 115).
There is growing evidence that the NI is a key player in mediat-
ing brainstem-elicited theta rhythm (47, 53, 116). In addition to
projections to the SuM, there are strong relaxin-3-containing NI
projections to other regions subserving theta rhythm generation,
such as medial septum (48–50), reticularis pontine oralis, and the
hippocampus, as well as the median raphe, which is involved in
theta desynchronization [see (52) for review]. In fact, relaxin-3
projections to the medial septum have been shown to promote
hippocampal theta rhythm and are necessary for normal spatial
navigation of rats in a spontaneous alternation task (47). Thus,
the SuM is likely a further node at which this neuropeptide sys-
tem acts to regulate hippocampal theta activity and associated
cognitive/autonomic processes.
The lateral and medial preoptic areas of hypothalamus are also
rich in relaxin-3 projections and RXFP3. The LPO area contains
populations of neurons that have identified roles in thermoreg-
ulation (117, 118) and sleep-wakefulness (ventrolateral neurons)
(119), so it will be of interest, to assess the precise topography of
RXFP3 in these areas and to assess the effects of RXFP3 activa-
tion/inhibition in these regions on these physiological parameters,
particularly as our laboratory has anatomical and functional data
consistent with effects of relaxin-3 on sleep-wake activity in mice
(34, 120). Similarly, as discussed, the role of relaxin-3/RXFP3 sig-
naling in the medial preoptic area may be important in stress
responses in female rats and the possible regulation of CRH
neurons in the area (106).
RELAXIN-3/RXFP3 IN MOUSE HYPOTHALAMUS – SPECIES
DIFFERENCES
The distribution of relaxin-3 neurons and projections, as well as
the distribution of RXFP3 mRNA and binding sites in the mouse
brain, is regionally similar to that in the rat both generally through-
out the forebrain and within the hypothalamus (33, 34). Further-
more, the distribution of Rxfp3 mRNA in the C57BL6/J mouse
detailed in the Allen Brain Institute Brain Atlas (see text footnote 1)
using a digoxigenin-labeled RNA probe is similar to that observed
in our studies using radioactively labeled oligonucleotides (34)
(Table 1). However, a more detailed analysis is required to deter-
mine whether identical populations of neurons are targeted within
key hypothalamus areas, such as the arcuate, periventricular, PVN,
and SON of rat and mouse to assess whether relaxin-3 signaling
might regulate similar neuroendocrine processes in these species.
We have conducted several studies to assess the possible role of
relaxin-3/RXFP3 in food intake in mice (121). After the adminis-
tration of similar or higher levels of relaxin-3 or various RXFP3-
selective agonists (R3/I5, RXFP3-A2) used in studies on rats [see
(76) for review], we did not observe an increase in food intake of
satiated C57BL/6J mice. In more recent studies, we have observed
that the icv administration of the RXFP3 antagonist, R3(B1–22)R
(73) produced a reduction in the robust feeding that occurred in
mice offered access to regular chow after a 4 h period of isolated
housing in a novel cage without bedding and in the absence of food
(Smith and Gundlach, unpublished data). These particular con-
ditions are presumed to induce a level of stress, hypothermia, and
energy deficiency in the mice, which motivates their feeding; and
suggests that relaxin-3/RXFP3 signaling in mice may not influence
feeding significantly under basal conditions, but may play a role
under altered stress conditions. These possibilities are currently
being explored experimentally.
Consistent with these pharmacological studies, however, there
is no genotypic difference between relaxin-3 KO and wild type
littermates in bodyweight, total food consumption, or circadian
rhythm of food consumption (120, 122). These findings are in con-
trast to data obtained by Sutton et al. (123) in a separately derived
colony of relaxin-3 KO mice on a mixed C57BL6/J/SV129 back-
ground, which displayed a markedly reduced body weight relative
to wild type mice when both genotypes were fed a diet with a mod-
erately elevated fat content. However, subsequent studies of a null
mutation Rxfp3 KO mouse strain revealed no body weight-related
phenotype, but did reveal an identical circadian hypoactivity phe-
notype to the relaxin-3 KO mouse (120,124,125). This suggests the
relaxin-3 KO phenotype reported by Sutton et al. (123) was asso-
ciated with genetic differences independent of relaxin-3/RXFP3
[see (39)].
With regard to the specificity of pharmacological studies of
RXFP3 signaling in the mouse, while the presence of insulin-
like peptide 5 (INSL5) and RXFP4 in the mouse brain has been
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reported (126), these findings have not been independently val-
idated; and in a separate study, the presence of INSL5-sensitive
receptor binding sites could not be identified (127). Furthermore,
the ligand/receptor expression profile suggests the INSL5/RXFP4
system acts primarily within the gastrointestinal tract and large
intestine (28, 128). While it is possible that peripheral INSL5 sig-
naling may alter central (hypothalamic) function, at this stage no
such data is available.
CONCLUSION AND PERSPECTIVES
A decade of research has revealed the basic structural frame-
work of central relaxin-3/RXFP3 networks and their likely func-
tional importance in mammalian brain (27, 39, 76); and sev-
eral studies have highlighted the interaction between hypothal-
amic homeostatic systems and relaxin-3/RXFP3 signaling, pre-
dominantly in pharmacological and regulatory studies in the
rat. Together, these studies point to a role for relaxin-3/RXFP3
in regulating hypothalamic activity, with evidence suggesting
it does so via interactions with oxytocin, AVP, and/or CRH,
to modulate neuroendocrine function associated with stress,
feeding, and metabolism, and motivation and reward. Further
studies are now required to clarify the nature of these var-
ious effects and how they are coordinated and regulated by
hormonal and transmitter inputs onto relaxin-3 neurons and
integrated signaling at the level of hypothalamic loops (e.g.,
HPA, HPG axes). Recent research strongly suggests the relaxin-
3/RXFP3 system is an important regulator of the neuroendocrine
axis, with potential as a novel therapeutic target for the treat-
ment of neuroendocrine disorders and associated behavioral
dysfunction.
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